Phase 1 Metastatic Prostate Cancer Clinical Trials
14 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–14 of 14 trials
Recruiting
Phase 1
A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer
Metastatic Prostate Cancer (mCRPC)
Novartis Pharmaceuticals15 enrolled4 locationsNCT07174063
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Advanced Prostate CancerMetastatic Prostate Cancer
Genentech, Inc.210 enrolled25 locationsNCT05800665
Recruiting
Phase 1Phase 2
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Metastatic Prostate Cancer
AstraZeneca177 enrolled51 locationsNCT07181161
Recruiting
Phase 1
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
Prostate CancerMetastatic Prostate Cancer
University of California, San Francisco30 enrolled1 locationNCT07145177
Recruiting
Phase 1
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
Prostate Cancer PatientsRecurrent Prostate CancerOligometastatic Prostate Cancer (OMPC)+1 more
University of Wisconsin, Madison14 enrolled1 locationNCT07090148
Recruiting
Phase 1Phase 2
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Metastatic Prostate Cancer
AstraZeneca60 enrolled15 locationsNCT06267729
Recruiting
Phase 1
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Advanced Prostate CancerMetastatic Prostate CancerMetastatic Prostate Neuroendocrine Carcinoma
Brigham and Women's Hospital30 enrolled2 locationsNCT06062745
Recruiting
Phase 1
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Metastatic Prostate Cancer
ORIC Pharmaceuticals250 enrolled27 locationsNCT05413421
Recruiting
Phase 1
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Prostate CancerMetastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute37 enrolled3 locationsNCT06303713
Recruiting
Phase 1
A Phase 1 Study Investigating the Safety, Biodistribution, and Dosimetry of [68Ga]Ga-A9-6217 in Participants with Select Advanced or Metastatic Solid Tumors
advanced or metastatic small cell lung canceradvanced or metastatic prostate cancer
Alpha-9 Theranostics40 enrolled1 locationACTRN12625000268448
Recruiting
Phase 1
Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC
Metastatic Prostate CancerMetastatic Castration-resistant Prostate CancerCastration-resistant Prostate Cancer
Shanghai Changzheng Hospital3 enrolled1 locationNCT06895811
Recruiting
Phase 1Phase 2
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Pancreatic CancerMetastatic Prostate Cancer
ImmunoGenesis71 enrolled1 locationNCT06782555
Not Yet Recruiting
Phase 1
Understanding the role of TLX591 in patients with metastatic Prostate cancer who failed 2 cycles of Lutetium PSMA therapy
Metastatic Prostate Cancer
Mercy Radiology10 enrolled1 locationACTRN12623000216617
Terminated
Phase 1
A Phase I Clinical Trial of a Christchurch Medical Research Foundation (CMRF)-56+ Blood Dendritic Cell Preparation for the Immunotherapy of Metastatic Hormone Refractory Prostate Cancer
Patients with hormone refractory metastatic prostate cancer
Mater Medical Research Institute12 enrolled1 locationACTRN12607000450415